Simridarlimab

斯瑞利单抗

Report date: 2022/05/18 16:21:40

Base Information

Drug NameSimridarlimab

Drug Alias NameCD47xPD-L1 bispecific antibodyIBI322IBI-322IBI322

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionCluster of differentiation 47 inhibitorsProgrammed death-ligand 1 blockers

TargetsProgrammed death-ligand 1Cluster of differentiation 47

Therapy Area/IndicationsSolid tumoursBone Marrow NeoplasmsHematologic Neoplasms +[7]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesInnovent Biologics(Suzhou) Co Ltd

China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesInnovent Biologics(Suzhou) Co Ltd

Inactive CompaniesN/A

Active IndicationsSolid tumoursHematologic NeoplasmsLymphoma, T-Cell +[4]

Inactive IndicationsBone Marrow NeoplasmsLeukemia, Myeloid, AcuteNeoplasms

Other Information

ATC CodeN/A